Enlivex Therapeutics : Immediate Report - MarketScreener
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of...
Source: marketscreener.com
Oren Hershkovitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Oren Hershkovitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Oren Hershkovitz Today - Breaking & Trending Today
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure assessment (SOFA) scores and mortality for the 28-day period post treatment.Efficacy: Stand-alone analysis of the Allocetra™-treated patients, of which 78% had septic shock and 65% had invasive ventilation at screening, demonstrated substantial reductions in SOFA scores and 65% reduction in overall morta
Source: yahoo.com
Enlivex Stock Tanks 53% After Reporting Results For Phase 2 Study Of Allocetra
Shares of Enlivex Therapeutics Ltd. (ENLV) plunged over 53% on Thursday morning after company announces topline results of its phase II study evaluating Allocetra in patients with sepsis.
Source: rttnews.com
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel,...
Source: marketscreener.com
Enlivex Therapeutics : Purchase Agreement - Form 6-K -November 07, 2023 at 05:02 pm EST
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer ...
Source: marketscreener.com